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PAntiplatelet Therapy
Calcium-Channel Blockers Reduce
the Antiplatelet Effect of Clopidogrel
Jolanta M. Siller-Matula, MD,* Irene Lang, MD,† Guenter Christ, MD,† Bernd Jilma, MD*
Vienna, Austria
Objectives Because of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized that there might
be a drug-drug interaction between clopidogrel and dihydropyridines in patients with coronary artery disease.
Background Clopidogrel is activated by CYP3A4, which also metabolizes CCBs of the dihydropyridine class.
Methods Responsiveness to clopidogrel was assessed by the vasodilator-stimulated phosphoprotein (VASP) phosphorylation
assay and aggregometry in 200 patients with coronary artery disease undergoing percutaneous coronary intervention.
Results The platelet reactivity index (PRI) (in the VASP assay, normal range 69% to 100%) was higher in patients receiv-
ing both clopidogrel and CCBs (61%) as compared with patients receiving clopidogrel without CCBs (48%). The
absolute difference was 13% (95% confidence interval: 6% to 20%; p  0.001), and the relative difference ap-
proached 21%. A decreased platelet inhibition by clopidogrel (PRI 69%) was seen in 40% of patients with con-
comitant CCB treatment and in 20% of patients without concomitant treatment (chi-square test, p  0.008).
Intake of CCB remained an independent predictor of reduced platelet inhibition by clopidogrel after adjustment
for cardiovascular risk factors. Adenosine diphosphate-induced platelet aggregation was 30% higher in patients
on concomitant CCB treatment compared with patients without CCBs (p  0.046). Moreover, intake of CCBs was
associated with adverse clinical outcome. In vitro incubation with CCBs (nimodipine, verapamil, amlodipine, and
diltiazem) did not alter the PRI or the adenosine diphosphate–induced platelet aggregation of patients taking
clopidogrel. This finding indicates that the negative effect occurs in vivo, conceivably at the level of the CYP3A4
cytochrome.
Conclusions Coadministration of CCBs is associated with decreased platelet inhibition by clopidogrel. (J Am Coll Cardiol
2008;52:1557–63) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.055(
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whe effect of clopidogrel is not uniform in all patients, and
ecreased platelet inhibition by clopidogrel is seen in about
0% of patients taking clopidogrel and is associated with an
-fold increased risk of major adverse cardiac events (1–4).
lopidogrel is metabolized to an active thiol metabolite by
he CYP3A4 enzyme (5,6). The variability in the response
o clopidogrel has been, at least in part, linked to its
etabolism by cytochrome P450 enzymes (2). For example,
ome lipophilic statins may inhibit the CYP3A4 enzyme,
nd therefore decrease the formation of the active metabo-
ite of clopidogrel (7). Calcium-channel blockers (CCBs),
nother frequently used class of cardiovascular drugs, also
nhibit CYP3A4 (8–10).
Therefore, we hypothesized that intake of CCBs may be
ssociated with decreased responsiveness to clopidogrel. We
erformed the vasodilator-stimulated phosphoprotein
rom the Departments of *Clinical Pharmacology and †Cardiology, Medical Uni-
ersity of Vienna, Vienna, Austria. This study was supported by a grant from the
ubiläumsfond of the Austrian National Bank (#12565).U
Manuscript received March 17, 2008; revised manuscript received June 16, 2008,
ccepted July 2, 2008.VASP) phosphorylation assay and platelet aggregometry.
he VASP assay is a fairly new platelet function assay
11–13). It is specific for clopidogrel and other P2Y12
ntagonists in the absence of cilostazol (14,15), and it can be
sed to quantify platelet inhibition by clopidogrel (16). It
as been shown that adjusting the clopidogrel loading dose
ccording to the platelet reactivity index (PRI) in the VASP
ssay improves the clinical outcome in patients with de-
reased platelet inhibition by clopidogrel (17,18).
See page 1564
This prospective study aimed to compare the responsiveness
o clopidogrel in 200 coronary artery disease (CAD) patients
ith and without concomitant treatment with CCBs.
ethods
tudy design. This was a prospective observational study.
atients were followed up for 6 months. The study protocol
as approved by the ethics committee of the Medical
niversity of Vienna in accordance with the Declaration of
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CCBs and Clopidogrel Interaction November 4, 2008:1557–63Helsinki. Written informed con-
sent was obtained from all study
participants before study entry.
Two hundred patients with
CAD undergoing percutaneous
coronary intervention (PCI) were
enrolled. Patients had been on a
regimen of clopidogrel (75 mg/
day) therapy for 3 months on
average (since at least 1 week
before study entry) or had re-
ceived a 600 mg loading dose of
clopidogrel (at least 2 h before
study entry). The primary end
point was a composite of death
from cardiovascular causes, non-
fatal myocardial infarction, stent
thrombosis, and revascularization
(PCI or coronary artery bypass
graft [CABG] surgery). During
the study, samples of 20 healthy
volunteers with a normal platelet
unction were run in parallel to exclude any potential shifts
n the readouts of the platelet function tests.
lood sampling. Blood samples from patients were ob-
ained from the arterial sheath (6-F) in the catheterization
aboratory. Blood samples from volunteers were obtained
rom an antecubital vein, using a 21-gauge needle.
nalysis of VASP phosphorylation by flow cytom-
try. To determine the VASP phosphorylation state of
hole blood, we used a standardized flow cytometric assay
Platelet VASP, BioCytex, Marseille, France), which is an
daptation of the method of Schwarz et al. (19). Blood
amples collected in 3.8% sodium citrate (Vacutainer, Bec-
on Dickinson Biosciences, Vienna, Austria) were incubated
n vitro with ADP and/or prostaglandin E1 (PGE1) before
xation. After 10 min, platelets were permeabilized, labeled
ith a primary monoclonal antibody against serine 239-
hosphorylated VASP (clone 16C2) or its isotype, followed
y a secondary fluorescein isothiocyanate-conjugated poly-
lonal goat-antimouse antibody. All procedures were per-
ormed at room temperature. Platelet geometric mean
uorescence intensity (MFI) was determined using a flow
ytometer (FACSCalibur System, Becton Dickinson Bio-
ciences). The platelet population was identified by its
orward and side scatter distribution, and 10,000 platelet
vents were gated and analyzed for MFI. Platelet reactivity
as expressed as the PRI, calculated as: PRI%  [(MFI
PGE1) – MFI (PGE1  ADP)/MFI (PGE1)]  100.
he ratio is expressed as mean percentage platelet reactivity,
hich inversely correlates with the clopidogrel effect. The
ASP assay was performed within 24 h after blood sam-
ling. Using the test results from 20 healthy volunteers
ithout clopidogrel therapy, the reference value for the
ssay 69% to 100% was calculated by using a nonparametric
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CCB  calcium-channel
blocker
HR  hazard ratio
MFI  mean fluorescence
intensity
PCI  percutaneous
coronary intervention
PG  prostaglandin
PRI  platelet reactivity
index
VASP  vasodilator-
stimulated phosphoproteinercentile method (95%). The coefficient of variation of the sssay was 5% for duplicates and for testing the same
amples on 2 different days.
n vitro experiment. In 10 additional patients, who were
eceiving clopidogrel but not CCBs, PRI and aggregometry
ere measured before and after incubation of blood (10
in, 37°C) with 4 different CCBs: verapamil (Isoptin [90
g/ml], Abbott, Vienna, Austria), diltiazem (Dilzem [200
g/ml], Elan Pharma International, Ltd., Athlone, Ireland),
mlodipine (40 ng/ml, Sigma Aldrich, Vienna, Austria),
nd nimodipine (Nimotop [10 ng/ml], Bayer, Vienna,
ustria). The concentrations of CCBs are the maximum
oncentrations in plasma (Cmax) described (20–23).
ggregometry. Whole blood aggregation was determined
sing an impedance aggregometer (Multiple Platelet Func-
ion Analyzer/Multiplate Analyzer, Dynabyte Medical,
unich, Germany). The system detects the electrical im-
edance change due to the adhesion and aggregation of
latelets on 2 independent electrode-set surfaces in the test
uvette (24,25). A 1:2 mixture of 0.9% NaCl and whole
lood anticoagulated with hirudin (200 U/ml, Dynabyte,
unich, Germany) were stirred at 37°C for 3 min in the
est cuvettes; adenosine diphosphate (ADP [6.4 M,
ynabyte Medical, Munich, Germany]) was added, and the
ncrease in electrical impedance was recorded continuously
or 5 min. The mean values of the 2 independent determi-
ations are expressed as the area under the curve of the
ggregation tracing (24). The reference values for the test
re 29 to 118 U (26). The results measured by the Multiplate
nalyzer are reproducible with a 6% variability (24).
ample size estimation and statistical analysis. A sample
ize calculation was based on the observed mean  SD
61  17) of the PRI under clopidogrel treatment (27). We
alculated that we needed to include 200 patients to be able
o detect a 15% relative difference in PRI with a power of
5% and a 2-sided alpha value of 0.05. Normal distribution
as tested with the Kolmogorov-Smirnov test. Data are
xpressed as mean and SEM, SD, or 95% confidence
ntervals (CIs). Statistical comparisons were performed
ith the t test, the Mann-Whitney U test, and the chi-
quare test. Stepwise multivariable logistic regression
nalysis was used to estimate possible associations between
RI, platelet aggregation, and use of CCBs. The logistic
odel included age, serum creatinine levels, diabetes mel-
itus, arterial hypertension, hypercholesterolemia, previous
yocardial infarction, smoking, and use of beta-blockers,
tatins (lipophilic vs. hydrophilic), antidiabetic agents, and
ngiotensin-converting enzyme inhibitors. Two-year cumu-
ative incidence rates of composite clinical outcomes were
stimated by the Kaplan-Meier method. Stepwise multi-
ariable Cox proportional hazards regression modeling was
sed to estimate the independent effect of concomitant
CB treatment on clinical outcome. The Cox regression
odel included age, serum creatinine levels, diabetes mel-
itus, arterial hypertension, hypercholesterolemia, previous
yocardial infarction, smoking, and use of beta-blockers,tatins (lipophilic vs. hydrophilic), antidiabetic agents, and
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November 4, 2008:1557–63 CCBs and Clopidogrel Interactionngiotensin-converting enzyme inhibitors. A 2-tailed p
alue of 0.05 was considered significant for the primary
utcome variable (PRI in the VASP assay). All statistical
alculations were performed using commercially available
tatistical software (version 14.0, SPSS, Inc., Chicago,
llinois).
esults
atient demographics. Patient demographics are shown in
able 1. Patients receiving CCBs suffered more frequently
rom high blood pressure (91% vs. 78%; p  0.026) and
atient Demographics
Table 1 Patient Demographics
CCB
Yes, n  45 (22.5%) No, n  155 (77.5%)
Age, yrs 68 10 63 12*
Gender
Male 31 (69) 113 (86)
Female 15 (31) 41 (14)
Clopidogrel treatment
Chronic 39 (87) 142 (91)
Loading dose 6 (13) 13 (9)
Risk factors/medical history
Hypertension 41 (91) 122 (78)†
Smoking 19 (42) 87 (56)
Family history of CAD 10 (22) 43 (28)
Diabetes mellitus 22 (49) 45 (29)*
Hyperlipidemia 33 (73) 109 (70)
Prior myocardial infarction 16 (35) 53 (34)
Prior PCI 27 (60) 75 (48)
PAOD 9 (20) 16 (10)
CVD 7 (16) 17 (11)
Laboratory data
WBC, 109/l 8 2.5 8 3
Platelets, 109/l 219 80 230 64
CRP, mg/dl 0.8 1.3 1.8 3.5
Hb, g/dl 12 2 14 7
Fibrinogen, mg/dl 423 157 419 117
Creatinine, mg/dl 1.6 1.4 1.1 0.6*
Concomitant medications
ACE inhibitors 24 (54) 85 (55)
Statins 37 (83) 128 (83)
Lipophilic 30 (67) 108 (70)
Hydrophilic 7 (16) 20 (13)
Beta-blockers 27 (60) 130 (84)*
Antidiabetic agents 15 (33) 36 (23)
Insulin 7 (16) 11 (7)
Sulfonyl ureas 4 (9) 13 (8)
Metformin 0 (0) 6 (4)
Combination therapy 4 (9) 6 (4)
ASA 45 (100) 155 (100)
Clopidogrel 45 (100) 155 (100)
ata are reported as mean  SD or n (%). *p  0.01. †p  0.05.
ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; CAD  coronary artery
isease; CCB  calcium-channel blocker; CRP  C-reactive protein; CVD  cerebral vascular
isease; Hb  hemoglobin; PAOD  peripheral arterial occlusive disease; PCI  percutaneous
oronary intervention; WBC  white blood cells.iabetes mellitus (49% vs. 29%; p  0.007) as comparedith patients not taking CCBs. These risk factors and
igher age were associated with increased serum creatinine
alues in patients taking CCBs (p  0.05).
eference values for the PRI. Using the test results of
olunteers without clopidogrel therapy, the 95% reference
ange for the PRI was 69% to 100%. Similarly, the cut-off
alue for the fourth quartile of PRI in CAD patients was
9%, indicating that 25% of patients on clopidogrel therapy
ad decreased platelet inhibition by clopidogrel (Fig. 1).
Figure 1 Distribution of the PRI
Patients were on a regimen of clopidogrel therapy (n  200), and healthy vol-
unteers were drug free (n  20). The dotted line represents the lower limit of
the normal range of the vasodilator-stimulated phosphoprotein assay (69%
platelet reactivity index [PRI]).
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CCBs and Clopidogrel Interaction November 4, 2008:1557–63he PRI in patients taking clopidogrel and in volunteers not
aking clopidogrel exhibited a normal distribution (Fig. 1).
he mean PRI in patients was 52% (SD 21%).
CBs enhance platelet reactivity in patients on clopi-
ogrel. A total of 93% of patients treated with CCBs were
aking dihydropyridines (Table 2). The PRI was 21% higher
n patients receiving CCBs (61% PRI) as compared with
atients not taking CCBs (48% PRI; absolute difference
3%; 95% CI: 6% to 20%; p  0.001) (Fig. 2A). This
ignificant difference was also seen in the largest subgroup of
atients treated with amlodipine (p 0.001) (Table 2). The
istribution of PRI values among patients treated with
CBs was shifted to the right, compared with patients not
reated with CCBs (Fig. 3). A decreased platelet inhibition
y clopidogrel (PRI 69%) was seen in 40% and 20% of
atients with and without concomitant treatment CCB
reatment, respectively (chi-square test p  0.008). The
ignificant increase in PRI in patients receiving CCBs
ersisted after adjustment for CAD risk factors and other
ardiac medication (p  0.002). There was no apparent
ifference in PRI values between different groups of CCBs
Table 2). Moreover, differences in baseline characteristics
etween patients with or without CCB treatment did not
ffect the PRI: the PRI was not altered by high blood
ressure, diabetes mellitus, age, increased serum creatinine
alues, or use of beta-blockers, as tested by univariate
nalysis (U test and Spearman rank-sum correlation test).
imilarly, there was no difference in PRI values among
atients presenting with stable angina, unstable angina, or
yocardial infarction; and there was no difference in PRI
alues for other medications such as beta-blockers,
ngiotensin-converting enzyme blockers, antidiabetic
gents, and statins. Platelet inhibition by clopidogrel was
ot significantly altered by intake of lipophilic statins (50%
RI) as compared with patients without intake of statins
52% PRI). Up to 40 mg, there was no dose-dependent
ncrease in PRI by intake of lipophilic statins such as
torvastatin. The 80-mg dose of atorvastatin was associated
ith higher PRI values (60%; p  0.05), although the small
ample size in this subgroup (n  13) does not allow us to
PRI in the VASP Phosphorylation Assay ofClopidogrel Patients Treated With Different Clas
Table 2 PRI in the VASP Phosphorylation AsClopidogrel Patients Treated With D
n (%)
Patients treated with CCBs 45 (23)
D
B
Patients not treated with CCBs 155 (77)
Data are reported as mean  SD or n (%).
CCB  calcium-channel blocker; PRI  platelet reactivity index; VAraw any conclusions.ffect of concomitant cardiac medication on ADP-
nduced platelet aggregation. ADP-induced platelet ag-
regation was 30% higher in patients being treated with
oth clopidogrel and CCBs (52 U) as compared with
atients treated with clopidogrel but not CCBs (40 U; 95%
I: 0.3 to 20; p  0.046) (Fig. 2B). This difference,
owever, lost significance when it was adjusted for diabetes
nd beta-blocker intake. Differences in baseline character-
Figure 2 Negative Interaction Between CCBs and Clopidogrel
(A) The platelet reactivity index (PRI) in the vasodilator-stimulated phosphopro-
tein phosphorylation assay and (B) adenosine diphosphate (ADP)-induced
platelet aggregation in patients with or without calcium-channel blocker (CCB)
treatment are shown. Data are presented as mean and 95% confidence inter-
vals. *p  0.046, **p  0.001; patients treated with CCBs compared with
patients not treated with CCBs.
f CCBs
of
nt Classes of CCBs
CCBs Used, n (%) PRI (%), Mean  SD
61 18
pyridines 42 (93)
dipine 35 (78) 62 18
ndipine 3 (7) 55 24
ipine 3 (7) 49 15
ldipine 1 (2) 71
hiazepine 3 (7)
zem 3 (7) 58 17
48 21
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November 4, 2008:1557–63 CCBs and Clopidogrel Interactionstics between patients with or without CCB therapy did
ot affect the ADP-induced platelet aggregation: the ADP-
nduced platelet aggregation was not altered by high blood
ressure, diabetes mellitus, age, increased serum creatinine
alues, and use of beta-blockers, as tested by univariate
nalysis (U test and Spearman rank-sum correlation test).
imilarly, there was no difference in the ADP-induced
latelet aggregation between patients presenting with stable
ngina, unstable angina, or myocardial infarction; and there
as no difference in ADP-induced platelet aggregation for
ther medications such as beta-blockers, angiotensin-
onverting enzyme blockers, antidiabetic agents, and statins
lipophilic vs. hydrophilic; data not shown).
ack of effect of CCBs in vitro. In vitro incubation of
Figure 3 Distribution of the PRI With
or Without Calcium-Channel Blockers
Distribution of the platelet reactivity index (PRI) in patients with or without
calcium-channel blocker treatment is shown. The dotted line represents the
lower limit of the normal range of the vasodilator-stimulated phosphoprotein
assay (69% PRI).lood from patients administered clopidogrel with CCBsnimodipine, verapamil, amlodipine, and diltiazem) slightly
ut insignificantly decreased the average PRI as compared
ith the control group (average absolute difference: 6% to
3%). Similarly, incubation with CCBs did not alter the
DP-induced platelet aggregation (absolute difference:
3.5 to 3 U; data not shown). In summary, CCBs did not
irectly affect platelet function as measured by either test
ystem.
utcome. The composite end point occurred more fre-
uently among patients with concomitant CCB treatment
25%) than among patients without concomitant CCB
reatment (8%; crude hazard ratio [HR]: 3.9, p  0.001,
5% CI: 1.7 to 8.5; adjusted HR: 3.5, p  0.005, 95% CI:
.4 to 8.6) (Fig. 4). The composite end point was driven by
he higher rate of revascularization procedures.
iscussion
he most important finding is that intake of CCBs is
ssociated with a relative increase in platelet reactivity
index) by 21% (Fig. 2A). To our knowledge, no trial has
nvestigated the drug-drug interaction between clopidogrel
nd CCBs in the VASP assay. The VASP assay is the most
pecific test for clopidogrel action. It measures the inhibi-
ion of clopidogrel’s biochemical target, the P2Y12 receptor
nd its intracellular signalling: the PGE1-stimulated, cyclic
denosine monophosphate-dependent phosphorylation of
ASP (2,28). The VASP assay has been validated (29) and
ound to be predictive for stent thrombosis and cardiac
dverse events after coronary artery stenting (16,28,30).
ggregometry consistently showed that intake of CCBs was
ssociated with reduced efficacy of clopidogrel to inhibit
latelet aggregation (Fig. 2B).
Figure 4 Cumulative Kaplan-Meier
Estimates of Composite End Point
Cumulative Kaplan-Meier estimates of the rates of the composite end point
during the 6-month follow-up period. Blue line  patients without calcium-
channel blocker; red line  patients with calcium-channel blocker. Crude
hazard ratio  3.9; p  0.001; 95% confidence interval 1.7 to 8.5; adjusted
hazard ratio  3.5; p  0.005; 95% confidence interval 1.4 to 8.6.
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CCBs and Clopidogrel Interaction November 4, 2008:1557–63The cut-off value for the VASP assay indicating de-
reased platelet inhibition by clopidogrel was based on the
ower limit of the normal range (69% PRI) (Fig. 1). This is
onsistent with another study in 39 patients untreated with
lopidogrel, and confirms the external validity of the test
31). It indicates that 25% of patients had a decreased
esponse to clopidogrel. When comparing patients with and
ithout CCB therapy, the prevalence of decreased platelet
nhibition by clopidogrel was 40% and 20%, respectively. A
igher rate of decreased platelet inhibition by clopidogrel in
he CCB group corresponded to a 3.9 higher risk for the
ccurrence of the composite end point as compared with
atients not having CCB treatment.
However, our cut-off value (69% PRI) may still under-
stimate the PRI value necessary for true efficacy. Receiver-
perator characteristics curve analysis has previously shown
hat a PRI value of 48% was most sensitive to predict
dverse cardiovascular events (28). Applying such a cut-off
alue of 48% PRI to our patients would result in 64% of
atients with decreased platelet inhibition by clopidogrel.
onsistent with our results, the prevalence of decreased
latelet inhibition by clopidogrel would then be higher
mong patients treated with CCBs (71%) as compared with
atients not treated with CCBs (50%; p  0.05).
There is only 1 small study, involving 6 patients with
eripheral arterial obstructive disease, which investigated
latelet inhibition by clopidogrel when added to ongoing
ifedipine therapy (32). Clopidogrel inhibited platelet ag-
regation by 30%. However, the study design, including the
ery small sample size, does not allow any conclusion to be
ade about the drug–drug interaction between clopidogrel
nd nifedipine.
Our in vitro experiments indicate that CCBs do not
irectly affect platelet inhibition by clopidogrel as measured
y the VASP assay or aggregometry. This finding supports
he concept that CCBs conceivably alter the in vivo bio-
ransformation of clopidogrel at the level of the CYP3A4
ytochrome. Clopidogrel is a pro-drug, which requires
epatic bioactivation by the cytochrome P450 isoform 3A4
o generate the active metabolites (2). Also, diltiazem and
ihydropyridines are highly metabolized (60% to 90%) in
he liver by the cytochrome P450 isoform 3A4 to inactive
etabolites (10,33,34). Clopidogrel is hydrolyzed in vivo to
n inactive metabolite, which represents more than 85% of
he circulating drug-related compounds in plasma (35). The
ntrahepatocyte level of clopidogrel, which is available for
etabolism, is 10-fold lower than the plasma level of the
nactive carboxylic acid metabolite of clopidogrel (7). The
lasma concentration of the main circulating active metab-
lite of clopidogrel is very low, and generally below detec-
ion limits (0.25 ng/ml) (36). For comparison, the plasma
oncentrations of CCBs are much higher (amlodipine, 41
g/ml; diltiazem, 200 ng/ml; nisoldipine, 100 ng/ml)
20,22,37). The degree of competitive inhibition between 2
ubstrates depends on the relative affinity of the substrates
or the binding site of CYP3A4 and their relative concen-rations (7). As CCBs inhibit CYP3A4 (8–10), they may
nhibit clopidogrel’s metabolism. Our results call for formal
linical trials that study the effects of CCBs on the phar-
acokinetics of clopidogrel to substantiate these seminal
bservations. Moreover, it will be interesting to investigate
possible effect of CCBs on prasugrel.
A drug–drug interaction study showed that the potent
YP3A4 inhibitor ketoconazole significantly reduced the
evel of clopidogrel’s active metabolite (35). Moreover,
oncomitant treatment with ketoconazole decreased platelet
nhibition in response to clopidogrel as measured by aggre-
ometry. Another study showed that the CYP3A4 inhibitor
traconazole significantly decreased the ability of clopidogrel
o inhibit platelet aggregation (38). Finally, a negative effect
f statins on clopidogrel has been reported on the level of
YP3A4. Some studies suggested that lipophilic statins
atorvastatin, lovastatin, and simvastatin) may competitively
nhibit CYP3A4 and decrease the generation of clopi-
ogrel’s active metabolite, reducing the antiplatelet effect of
lopidogrel (7,39,40). On the contrary, other reports were
ot able to confirm this findings (41–46). Similarly, we did
ot observe any drug–drug interaction between clopidogrel
nd lipophilic statins as measured with both assays in the
urrent study.
tudy limitations. In our study, the largest subgroup of
CBs was amlodipine. Further studies are needed to
onfirm a similar effect for other CCBs and to examine
hether this effect is a class effect. Additional limitations are
hat the duration of CCB therapy as well as the true baseline
or platelet reactivity in both groups was unknown.
onclusions
oadministration of CCBs and clopidogrel is associated
ith a decreased response to clopidogrel.
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